Clinical trial · Clinical audiology← The news desk

✦ The Dispatch

Atorvastatin for the Prevention of Cisplatin-Induced Ototoxicity: A Randomized Controlled Trial

A dispatch from PubMed — filed

Cisplatin is used to treat a variety of tumors, it has a significant ototoxic effect; as studies show that about 40% to 70% of patients treated with cisplatin suffer hearing loss to some extent, which may lead to social isolation, anxiety, depression, and an overall negative effect on quality of life....

Continue reading at PubMed

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

If atorvastatin demonstrates significant protective efficacy in this RCT, oncology-audiology teams should consider evaluating it as an otoprotective co-treatment — full results and effect size must be reviewed before any protocol change.

✦ Why It Matters ✦

Cisplatin-induced ototoxicity is a major quality-of-life burden for cancer survivors, and a widely available, low-cost drug like atorvastatin could represent a scalable otoprotective strategy if proven effective.

✦ Key Points ✦
  1. 01Cisplatin-induced ototoxicity affects 40–70% of treated cancer patients, causing permanent hearing loss.
  2. 02RCT design randomly assigned participants to atorvastatin or placebo alongside cisplatin chemotherapy.
  3. 03Atorvastatin is a widely available, low-cost statin with a known safety profile.
  4. 04Study directly addresses an unmet need — currently no FDA-approved otoprotective agent exists for cisplatin.
  5. 05Full results and magnitude of hearing protection effect are critical to assessing clinical applicability.
✦ Claims & Evidence ✦

Cisplatin-induced ototoxicity affects 40–70% of patients treated with cisplatin.

studysupported

Atorvastatin can prevent or reduce cisplatin-induced ototoxicity.

studyunclear
✦ Research metadata ✦
PMID
43031616
DOI
10.2147/DDDT.S649303.
Journal
Drug Design, Development and Therapy
Publication type
research_article
Evidence level
1b
Population
Cancer patients receiving cisplatin chemotherapy
Intervention
Atorvastatin (co-administered with cisplatin)
Comparator
Placebo

Primary outcomes

Incidence and severity of cisplatin-induced ototoxicity; Audiometric threshold shifts post-treatment

✦ Related stories ✦